Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients
Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin. Patients with mild/moderate hypertension and hypercholest...
Gespeichert in:
| Veröffentlicht in: | Journal of comparative effectiveness research 2016-07, Vol.5 (4), p.355-364 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 4 |
| container_start_page | 355 |
| container_title | Journal of comparative effectiveness research |
| container_volume | 5 |
| creator | Kónyi, Attila Sárszegi, Zsolt Hild, Gábor Gaszner, Balázs |
| description | Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin.
Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol.
At 6 months, 91% of 2241 evaluable patients achieved blood pressure target ( |
| doi_str_mv | 10.2217/cer-2016-0003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1802736346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1802736346</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-ea20f200ff6e672e96d3f32ae049dad89471c0fc3f3fb8791cdac656e5a33e083</originalsourceid><addsrcrecordid>eNp1kE1PxCAQhonRuGb16NVw9ILy0dL2aIxfiYkH9UxYOmzRbluBavrvZe3qzRMD88yb4UHolNELzllxacATTpkklFKxh444zTiRgon9v5rmC3QSwlsiqCyzKueHaMELXuWM8SP09awtxAnrrsZgLZjoPqGDEHBvsek3K9dBnbrRNdMAPkIXEvCDm6ZvIUTwfUva_gu869Y4NuD1MGHX4catG3L5CX6aS-_COx50dNDFcIwOrG4DnOzOJXq9vXm5viePT3cP11ePxIhMRAKaU8sptVaCLDhUshZWcA00q2pdl1VWMEOtSY92VRYVM7U2MpeQayGAlmKJzufcwfcfY1pXbVww0La6g34MipWUF0KKTCaUzKjxfQgerBq822g_KUbVVrdKutVWt9rqTvzZLnpcbaD-o3_lJqCaATvG0UMw6ecG1HxLE84kuf-EfwPSLJE9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1802736346</pqid></control><display><type>article</type><title>Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients</title><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kónyi, Attila ; Sárszegi, Zsolt ; Hild, Gábor ; Gaszner, Balázs</creator><creatorcontrib>Kónyi, Attila ; Sárszegi, Zsolt ; Hild, Gábor ; Gaszner, Balázs</creatorcontrib><description>Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin.
Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol.
At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (<140/90 mmHg); low-density lipoprotein cholesterol targets, <3, <2.5 and 1.8 mmol/l, were achieved by 67, 49 and 40% of patients, respectively. Adverse events (4.4%) were mostly mild.
Lisinopril-amlodipine plus rosuvastatin was well tolerated and effective in patients with mild/moderate hypertension and hypercholesterolemia at high/very high CV risk.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer-2016-0003</identifier><identifier>PMID: 27295112</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Amlodipine ; Anticholesteremic Agents - therapeutic use ; Antihypertensive Agents - therapeutic use ; cardiovascular risk ; Cholesterol ; diabetes mellitus ; Humans ; hypercholesterolemia ; Hypercholesterolemia - drug therapy ; hypertension ; Hypertension - drug therapy ; lisinopril-amlodipine ; Prospective Studies ; rosuvastatin</subject><ispartof>Journal of comparative effectiveness research, 2016-07, Vol.5 (4), p.355-364</ispartof><rights>Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-ea20f200ff6e672e96d3f32ae049dad89471c0fc3f3fb8791cdac656e5a33e083</citedby><cites>FETCH-LOGICAL-c343t-ea20f200ff6e672e96d3f32ae049dad89471c0fc3f3fb8791cdac656e5a33e083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27295112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kónyi, Attila</creatorcontrib><creatorcontrib>Sárszegi, Zsolt</creatorcontrib><creatorcontrib>Hild, Gábor</creatorcontrib><creatorcontrib>Gaszner, Balázs</creatorcontrib><title>Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin.
Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol.
At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (<140/90 mmHg); low-density lipoprotein cholesterol targets, <3, <2.5 and 1.8 mmol/l, were achieved by 67, 49 and 40% of patients, respectively. Adverse events (4.4%) were mostly mild.
Lisinopril-amlodipine plus rosuvastatin was well tolerated and effective in patients with mild/moderate hypertension and hypercholesterolemia at high/very high CV risk.</description><subject>Amlodipine</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>cardiovascular risk</subject><subject>Cholesterol</subject><subject>diabetes mellitus</subject><subject>Humans</subject><subject>hypercholesterolemia</subject><subject>Hypercholesterolemia - drug therapy</subject><subject>hypertension</subject><subject>Hypertension - drug therapy</subject><subject>lisinopril-amlodipine</subject><subject>Prospective Studies</subject><subject>rosuvastatin</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PxCAQhonRuGb16NVw9ILy0dL2aIxfiYkH9UxYOmzRbluBavrvZe3qzRMD88yb4UHolNELzllxacATTpkklFKxh444zTiRgon9v5rmC3QSwlsiqCyzKueHaMELXuWM8SP09awtxAnrrsZgLZjoPqGDEHBvsek3K9dBnbrRNdMAPkIXEvCDm6ZvIUTwfUva_gu869Y4NuD1MGHX4catG3L5CX6aS-_COx50dNDFcIwOrG4DnOzOJXq9vXm5viePT3cP11ePxIhMRAKaU8sptVaCLDhUshZWcA00q2pdl1VWMEOtSY92VRYVM7U2MpeQayGAlmKJzufcwfcfY1pXbVww0La6g34MipWUF0KKTCaUzKjxfQgerBq822g_KUbVVrdKutVWt9rqTvzZLnpcbaD-o3_lJqCaATvG0UMw6ecG1HxLE84kuf-EfwPSLJE9</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Kónyi, Attila</creator><creator>Sárszegi, Zsolt</creator><creator>Hild, Gábor</creator><creator>Gaszner, Balázs</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients</title><author>Kónyi, Attila ; Sárszegi, Zsolt ; Hild, Gábor ; Gaszner, Balázs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-ea20f200ff6e672e96d3f32ae049dad89471c0fc3f3fb8791cdac656e5a33e083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Amlodipine</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>cardiovascular risk</topic><topic>Cholesterol</topic><topic>diabetes mellitus</topic><topic>Humans</topic><topic>hypercholesterolemia</topic><topic>Hypercholesterolemia - drug therapy</topic><topic>hypertension</topic><topic>Hypertension - drug therapy</topic><topic>lisinopril-amlodipine</topic><topic>Prospective Studies</topic><topic>rosuvastatin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kónyi, Attila</creatorcontrib><creatorcontrib>Sárszegi, Zsolt</creatorcontrib><creatorcontrib>Hild, Gábor</creatorcontrib><creatorcontrib>Gaszner, Balázs</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kónyi, Attila</au><au>Sárszegi, Zsolt</au><au>Hild, Gábor</au><au>Gaszner, Balázs</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>5</volume><issue>4</issue><spage>355</spage><epage>364</epage><pages>355-364</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin.
Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol.
At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (<140/90 mmHg); low-density lipoprotein cholesterol targets, <3, <2.5 and 1.8 mmol/l, were achieved by 67, 49 and 40% of patients, respectively. Adverse events (4.4%) were mostly mild.
Lisinopril-amlodipine plus rosuvastatin was well tolerated and effective in patients with mild/moderate hypertension and hypercholesterolemia at high/very high CV risk.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27295112</pmid><doi>10.2217/cer-2016-0003</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6305 |
| ispartof | Journal of comparative effectiveness research, 2016-07, Vol.5 (4), p.355-364 |
| issn | 2042-6305 2042-6313 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1802736346 |
| source | Open Access: PubMed Central; MEDLINE; Alma/SFX Local Collection |
| subjects | Amlodipine Anticholesteremic Agents - therapeutic use Antihypertensive Agents - therapeutic use cardiovascular risk Cholesterol diabetes mellitus Humans hypercholesterolemia Hypercholesterolemia - drug therapy hypertension Hypertension - drug therapy lisinopril-amlodipine Prospective Studies rosuvastatin |
| title | Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A47%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20effectiveness%20of%20combined%20antihypertensive%20and%20cholesterol-lowering%20therapy%20in%20high-/very%20high-risk%20patients&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=K%C3%B3nyi,%20Attila&rft.date=2016-07-01&rft.volume=5&rft.issue=4&rft.spage=355&rft.epage=364&rft.pages=355-364&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer-2016-0003&rft_dat=%3Cproquest_cross%3E1802736346%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1802736346&rft_id=info:pmid/27295112&rfr_iscdi=true |